Last updated: May 13, 2026
Penicillin G Benzathine Suppliers (API, Finished Dose, and Contract Manufacturing)
Penicillin G benzathine is sold as a sterile injectable antibiotic under multiple brand and private-label labels worldwide. Supplier coverage splits into (1) active pharmaceutical ingredient manufacturers (penicillin G benzathine API and/or sterile-drug substance intermediates), (2) finished-dose sterile injection manufacturers, and (3) distributors/importers that supply regional markets.
Because “supplier” can mean different roles, the market typically maps as:
- API manufacturers that supply penicillin-related intermediates and penicillin G benzathine drug substance to sterile injectable formulators.
- Sterile finished-dose manufacturers that package, sterilize, and release penicillin G benzathine injections under NDA/ANDA labels or distributor arrangements.
- Regional distributors/importers that supply hospitals and tenders.
Who manufactures penicillin G benzathine injection finished product?
Penicillin G benzathine is commonly produced by manufacturers that operate sterile injectable facilities and hold market authorizations for the finished injection in their territories. In practice, finished-product supply is concentrated among a limited set of global sterile-injectable suppliers and regional generic manufacturers.
Typical finished-dose supply structure
- Sterile drug product manufacturers: manufacture and fill sterile vials/syringes, then package for national registration.
- License holders and distributors: sell under local labels, often importing from the sterile injectable manufacturer.
Common finished-dose forms
- Intramuscular injection, typically powder with reconstitution instructions (or prefilled presentation depending on jurisdiction), in varying strengths (notably commonly 1.2 million units and 2.4 million units in many markets).
Which companies supply penicillin G benzathine API (drug substance)?
Penicillin G benzathine drug substance supply is usually handled by specialized penicillin chemistry manufacturers and penicillin-related API producers with relevant fermentation, purification, and crystallization capabilities.
API supply chain characteristics
- Penicillin manufacturing supply is constrained by:
- fermentation capacity and upstream feedstock sourcing,
- penicillin isolation and crystallization controls (polymorph and impurity profiles),
- regulatory quality systems for beta-lactam APIs and sterile-drug substance handling.
- Many finished-dose firms do not produce drug substance in-house and procure API from certified suppliers.
Are penicillin G benzathine generics supplied by multiple approved ANDA holders?
Penicillin G benzathine is often supplied as generic or multisource sterile injectable therapy in many countries, with competition driven by:
- tender pricing for hospital procurement,
- supply continuity for sterile injectables,
- regulatory batch release and lot availability.
In the US, the practical supplier landscape is best evaluated through the FDA Orange Book entries for the relevant strengths and dosage forms, and via FDA drug listing and label holders for injectable presentations.
What is the Orange Book status of penicillin G benzathine in the US?
The US “Orange Book status” (listed patents/exclusivity) depends on each specific strength, dosage form, and NDA/label. For some older, established anti-infectives, patent exclusivity is typically not a binding barrier to generic supply, but the key operational constraint is sterile injectable manufacturing and consistent product quality/availability.
What to check for supplier due diligence
- Whether an approved NDA exists versus only legacy labels.
- Whether any listed patents or exclusivity block specific competitors for a specific label/strength.
- Whether there are multiple approved ANDAs across strengths and packaging configurations.
When does penicillin G benzathine lose exclusivity for specific labels?
Exclusivity is label-specific and jurisdiction-specific. For established antibiotic injectables, supplier timelines are typically governed by:
- expiration of any remaining label-specific exclusivity,
- manufacturing site capacity and regulatory approvals,
- ongoing inspections and batch-release performance.
Operationally, new entry risk is driven less by exclusivity and more by supply continuity and regulatory compliance for sterile beta-lactams.
Which Paragraph IV challenges or patent litigations affect penicillin G benzathine supply?
For established antibiotic injectables like penicillin G benzathine, US supplier pressure can come more from:
- shortage-driven purchasing (FDA drug shortages, distributor allocations),
- sterile injectable plant downtime,
- quality recalls,
than from Paragraph IV litigation.
Patent-litigation impacts, when they exist, are usually tied to specific NDA/ANDA labels or formulation/packaging claims, not the foundational antibacterial ingredient.
What formulation and manufacturing/IP barriers exist for penicillin G benzathine?
Even when ingredient patent barriers are limited, sterile injectable supply can be constrained by manufacturing controls for penicillin stability and sterility.
Key technical bottlenecks in manufacturing
- Beta-lactam contamination control and validated cleaning
- Crystallization controls for benzathine salt consistency
- Moisture sensitivity and reconstitution performance
- Sterile filtration/fill validation and terminal sterilization controls (as applicable by process)
- Endotoxin and sterility testing release timelines
Why this matters for suppliers
- Contract sterile fill-finish capacity and validated aseptic/sterile operations can be the limiting factor.
- Regulatory batches can require longer lead times for sterile injectable release.
How does penicillin G benzathine compare with benzylpenicillin (penicillin G) and other IM penicillins for supplier mapping?
Supplier ecosystems overlap but are not identical:
- Penicillin G benzathine is a specific salt form designed for long-acting IM administration.
- Benzylpenicillin (penicillin G) and other penicillins may be supplied as sodium or potassium salts with different sterile-dose and formulation needs.
- Different regulatory labels and manufacturing conditions mean suppliers are often not fully interchangeable.
This impacts procurement because a shortage in benzathine salt supply may not be solvable by swapping to other penicillin forms without clinical and regulatory adjustments.
Commercial procurement: how do you evaluate penicillin G benzathine suppliers for tenders?
Procurement diligence for a sterile injectable antibiotic should target:
- confirmed market authorization in the destination country,
- sterile manufacturing site qualification and inspection history,
- batch release track record and lead times,
- ability to supply multiple strengths/packaging configurations,
- distributor network and cold-chain/handling requirements (often not cold-chain for dry powders, but packaging and reconstitution compliance is still critical).
Supplier scoring checklist (practical)
- Availability: consistent lot supply within tender lead times
- Compliance: GMP/sterility track record for beta-lactams
- Logistics: ability to support national distributor requirements
- Quality: impurity profile consistency across lots
- Documentation: CoA, sterility/endotoxin certificates, and batch traceability
Key Takeaways
- Penicillin G benzathine supply is typically dominated by a small set of sterile injectable finished-product manufacturers and a separate set of API/drug-substance suppliers.
- Market supply constraints are usually driven by sterile injectable manufacturing capacity, batch release performance, and GMP quality execution rather than patent barriers.
- Supplier evaluation for procurement or sourcing should focus on label authorization coverage, lot availability, sterile-manufacturing compliance, and validated manufacturing capability for beta-lactam sterile injectables.
FAQs
- What are the main penicillin G benzathine finished product strengths commonly procured internationally?
- Can penicillin G benzathine API suppliers also supply other penicillin salts like benzylpenicillin sodium?
- What documentation should a hospital or distributor require for penicillin G benzathine batch traceability?
- How do sterile injectable recalls or inspections typically impact short-term availability of penicillin G benzathine?
- What factors most affect lead times for penicillin G benzathine procurement in national tenders?
References
- FDA. Drug Products (Orange Book / Approved Drug Products with Therapeutic Equivalence Evaluations). U.S. Food and Drug Administration.
- FDA. Drug Shortages. U.S. Food and Drug Administration.
